Spotlight On... Swiss researchers developing implant to prevent Alzheimer's disease; U.K. startup gets FDA nod for 3-D imaging breath detection; LIM Innovations gets Medicare reimbursement; and more...

Researchers at École Polytechnique Fédérale De Lausanne in Lausanne, Switzerland have developed the prototype of an implant that could prevent Alzheimer's disease by releasing a steady of flow antibodies into the bloodstream. The antibodies then target plaque associated with the disease, and the device has shown promise in mice. More

@FierceMedDev: GE Healthcare hand-held ultrasound in pilot NHS test, $20M Nigerian health initiative. Article | Follow @FierceMedDev

@VarunSaxena2: The chart is just so darn startling/horrible. (Have mentioned it in stories about opioid abuse-deterrent tech.) More from the NYT | Follow @VarunSaxena2

> Cambridge, U.K.-based PneumaCare has received FDA clearance for its Thora-3DI imaging device to measure breathing via detection of chest and abdomen movement. More

> San Francisco-based LIM Innovations said its prosthetic socket, Infinite Socket, has been granted coverage by Medicare. More

> Alere noted that its anticoagulation monitoring test has issues with INR measurement that could lead to rare, but serious, adverse events. But that a recent study found no difference in rate of adverse events in patients with or without the test. More

Biotech News

@FierceBiotech: FierceBiotech Radio on GSK's CEO shakeup, Lilly's Alzheimer's uncertainty, and Valeant's latest disaster. More | Follow @FierceBiotech

@JohnCFierce: Too bad, if so. $SFY has a beautiful building in Paris. And after its recent Gallic eruption, Paris looks like home. Story | Follow @JohnCFierce

> BerGenBio secures a $25M capital raise for its first-in-class cancer drug. Story

> Lilly CEO's Korean tour sparks rumors of a biosimilars deal with Samsung. Article

> What's next for Gilead in oncology? More

Pharma News

@FiercePharma: UPDATED: Nasdaq exec says biotechs prime Asian unicorns for listings. More from FiercePharmaAsia | Follow @FiercePharma

@EricPFierce: First came the recall, then the FDA plant ban, now the warning letter to Emcure plant for faking data. More from FiercePharmaManufacturing | Follow @EricPFierce

@CarlyHFierce: J&J chief Gorsky suffers cuts in bonus, incentive pay, but still racks up $23.8M. News | Follow @CarlyHFierce

> Sanofi CEO considers moving HQ out of Paris to cut costs. Story

> Senators lambaste Turing for 'unethical' price hikes at latest drug price hearing. Article